Structure and Transcriptional Regulation of the Human Cystatin A Gene
THE 12-O-TETRADECANOYLPHORBOL-13-ACETATE (TPA) RESPONSIVE ELEMENT-2 SITE (-272 TO -278) ON CYSTATIN A GENE IS CRITICAL FOR TPA-DEPENDENT REGULATION*

Hidetoshi TakahashiDagger , Kazuhiro Asano, Motoshi Kinouchi, Akemi Ishida-Yamamoto, Kirk D. Wuepper§dagger , and Hajime Iizuka

From the Department of Dermatology, Asahikawa Medical College, 3-11 Nishikagura, Asahikawa 078, Japan and the § Department of Dermatology, The Oregon Health Sciences University, Oregon 97201

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Cystatin A, a cysteine proteinase inhibitor, is one of the precursor proteins of cornified cell envelope of keratinocytes and is expressed during the late stage of keratinocyte differentiation. We have isolated and characterized the human cystatin A gene. The cystatin A gene consists of three exons and two introns. The first, the second, and the third exons consist of coding sequences that are 66, 102, and 126 base pairs in length, respectively. The first and the second introns consist of 14 and 3.6 kilobase pairs, respectively. The transcription initiation site was located 55 base pairs upstream from the first translation site. The fragment, +77 to -2595 in the 5'-flanking region of the human cystatin A gene, was subcloned into a chloramphenicol acetyltransferase (CAT) reporter vector. The expression vector, p2672CAT, produced a significant CAT activity in transiently transfected SV40-transformed human keratinocytes (SVHK cells), that were further stimulated by 12-O-tetradecanoylphorbol-13-acetate (TPA), a potent protein kinase C activator. Sequence analysis of the gene detected three TPA responsive elements (TRE-1, TRE-2, and TRE-3) and one AP-2 site on the 5' upstream promoter region. Deletion analyses of the p2672CAT vector demonstrated that TRE-2, which was located between -272 and -278, was critical for the regulation by TPA. Gel shift analyses revealed that c-Jun, JunD, and c-Fos bound to the TRE-2 region and that the p2672CAT activity level was elevated by co-transfection with c-Jun and c-Fos or with JunD and c-Fos expression vectors. Furthermore, co-transfection of SVHK cells with the protein kinase C-alpha expression vector and the p2672CAT expression vector also resulted in an increased CAT activity. These results indicate that the 5'-flanking region of the human cystatin A gene confers promoter activity and contains a TRE (TRE-2) that mediates, at least in part, the enhanced expression of this gene by TPA.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Cystatin A is a cysteine proteinase inhibitor that belongs to family 1 of the cystatin superfamily. Cystatin A was originally isolated from polymorphonuclear granulocytes (1), but it has also been isolated from the spleen, liver, and epidermis (2-4). The primary structure of cystatin A consists of a polypeptide chain of 98 amino acid residues that is mainly distributed intracellularly (5). We have recently reported that cystatin A is identical to keratolinin, one of the precursor proteins of cornified cell envelope (CE)1 (6), which is formed during terminal differentiation of keratinocytes (7-9).

CE is a highly insoluble structure formed beneath the plasma membrane of keratinocytes during terminal differentiation (7-9). This structure is 15-20 nm thick and is stabilized by cross-link formation of precursor proteins by N-(gamma -glutamyl)lysine isodipeptide bonds and disulfide bonds, which are catalyzed by transglutaminase(s) and sulfhydryl oxidase, respectively (7, 8, 10).

In addition to cystatin A, several proteins have been implicated as precursors of CE, which include involucrin (11), loricrin (12), small proline-rich protein(s) (13), elafin (14), and envoplakin (15). Recent evidence suggests that involucrin is an early component of CE and provides a scaffold for the incorporation of other precursor proteins (14, 16).

TPA, which is a potent activator of protein kinase C (PKC), induces terminal differentiation of keratinocytes (17, 18). Recent studies have revealed that involucrin, loricrin, and transglutaminase 1 genes contain a TRE(s) in their 5'-flanking regions and that these TREs induce increased expression of these protein transcripts by TPA (19-23). We have previously shown that the mRNA level of cystatin A is also stimulated by TPA in SV40-transformed human keratinocytes (SVHK cells) (6).

SVHK cells are a well-established, immortalized cell line sharing features of normal human keratinocytes (24, 25). These cells express relatively high levels of cystatin A as compared with other cell lines, such as A432 and SCC13 (data not shown). In the present study, we have identified the structure of the human cystatin A gene by screening a human genomic library and by using the polymerase chain reaction (PCR). We have also analyzed the regulation of cystatin A promoter activity by using a CAT reporter vector, which was connected to the 5'-flanking region of the cystatin A gene.

    EXPERMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Cell Culture-- SV40-transformed human keratinocytes (SVHK cells) (24) were a generous gift from Dr. M. L. Steinberg (Department of Chemistry, City College of the City University of New York, NY). The cell line was cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 100 units/ml penicillin, and 100 µg/ml streptomycin and incubated at 37 °C with 5% CO2.

Screening of the Human Genomic DNA Library-- A human phage library was purchased from CLONTECH (Palo Alto, CA). A 448-bp human cystatin A cDNA was digested with EcoRI (6) and labeled with [32P]dCTP by the random priming method. Filter hybridization was used to screen 1 × 106 clones with a probe at 65 °C overnight in a solution composed of 1 M NaCl, 50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 0.1% SDS, and 5× Denhardt's solution (1× Denhardt's solution: 0.002% polyvinylpyrrolidone, 0.002% Ficol, 0.02% bovine serum albumin). Subsequently, the filters were washed three times for 10 min at room temperature with 2× SSC (1× SSC: 0.15 M NaCl, 0.0015 M sodium citrate), 0.05% SDS and twice for 1 h at 65 °C with 1× SSC, 0.1% SDS. The filters were then exposed to Kodak XAR V film at -70 °C for 2 days.

PCR Cloning Strategies-- PCR was performed to analyze the promoter, the first exon, and the first intron of cystatin A using the Promoter FinderTM DNA Walking Kit (CLONTECH, Palo Alto, CA). To isolate the promoter and the first exon, we performed the first long PCR with the AP1 primer (as described in the kit) and the HCA1 primer (5'-AGTGGCGGGTTTGGCCTCAGATAAGCCTGG-3'; +63 to +95). Subsequently, the second PCR was performed with the AP2 primer (as described in the kit) and the HCA2 primer (5'-AGATAAGCCTCCAGGTATCATTTTGCG-3'; +51 to +77). To isolate the first exon and the first intron, we performed the first long PCR with the AP3 primer (5'-GCCCTATAGTGAGTCGTATTAGGATGG-3') and the HCA3 primer (5'-CGCAAAATGATACCTGGAGGCTTATCT-3'; +63 to +95) The second PCR was performed with the AP4 primer (5'-ACCACGCGTGCCCTATAG-3') and the HCA4 primer (5'-GGAGGCTTATCTGAGGCCAAACCCGCCACT-3'; +66 to +95). The HCA 1-4 primers were determined by cDNA analysis of keratolinin (6). The long PCR kit was purchased from Takara Shuzo Co. (Otsu, Japan). The DNA was amplified for 35 cycles on a DNA cycler (Perkin-Elmer Corp., Norwalk, CT) at 98 °C for 20 s and then 68 °C for 15 min. The PCR products (pTA648, pTA2672, and pTA4.0) were subcloned into the pCRTM 2.1 vector (Invitrogen, San Diego, CA).

DNA Sequence-- The isolated clone (pcHCA) was digested with EcoRI and ligated into the pGEM-3Zf(+) vector. The constructed plasmids were denatured with 0.2 M sodium hydroxide. The single-stranded DNA was sequenced by the dideoxy chain termination method using the SP6 and T7 promoter primers (26).

Plasmid Constructs-- The HindIII, XbaI-digested fragments from the pTA2672 and pTA648 vectors were inserted into the promoterless 0-CAT plasmids (p2.5CAT and p648CAT, respectively). Deleted vectors p478CAT, p238CAT, and p68CAT were generated by PCR using oligonucleotides HCA5 (5'-CTGTATGTTAAACATTTCCAG-3'; -478 to -457), HCA6 (5'-CATTGTCAAAGAGAATGCAG-3'; -239 to -221), HCA7 (5'-GCTGTTTGTGGAAAATAAAG-3'; -69 to -50), and HCA2. Each TRE-deleted fragment was generated by PCR using the overlap extension method with oligonucleotides HCA8 (5'-CATCCTGTTTCTGAATTATGAAATC-3'; -274 to -244, deleted TRE-2 region), HCA9 (5'-TAATTCAGAACAGGATGGAACCAT-3'; -267 to -236, deleted TRE-2 region), HCA10 (5'-GCAAGTAGATGTCCTAACAAGCAT-3'; -211 to -180, deleted TRE-1 region), and HCA11 (5'-GTTAGGACATCAACTTGCCCACTTG-3'; -204 to -173, deleted TRE-1 region). To construct the p648Delta T1 vector, we performed two PCR amplifications using the AP-2 and HCA8 oligomers or the HCA9 and HCA2 oligomers with the p648CAT vector as the template. Next, we performed a PCR with the AP-2 and HCA2 oligomers using mixed products derived from the initial PCR. The second PCR product was subcloned into the pCRTM 2.1 vector. Using the T7 promoter oligomer, we performed sequence analysis to confirm the orientation of the promoter and to confirm the absence of the deleted portion. The deleted fragments, which were isolated by digestion with HindIII and XbaI, were inserted into the promoterless 0-CAT plasmid. The p648Delta T2 vector was constructed using the AP-2, HCA10, HCA11, and HCA2 oligonucleotides. Using the p648Delta T1 vector, we performed PCR with the AP-2, HCA10, HCA11, and HCA2 oligomers and constructed the p648Delta T12 vector. The beta -galactosidase expression vector was kindly supplied by Dr. T. Watanabe (Medical Institute of Bioregulation, Kyushu University, Japan). The PKC expression vectors were generous gifts of Dr. S. Ohno (Department of Molecular Biology, Yokohama City University School of Medicine) (27).

Transfection and the CAT Assay-- Transfection of plasmid DNA into cells was performed by the liposome method using Lipofectin (28). Typically, 5 µg of reporter plasmid and 2 µg of beta -galactosidase plasmid were co-transfected into 1 × 105 SVHK cells. The beta -galactosidase plasmid was used as the internal standard to normalize each transfection efficacy. After 48 h, cells were collected, and the CAT assay was performed (29). The enzyme activity level of beta -galactosidase in the transfected cell extracts was measured spectrophotometrically (26). Relative CAT activity is expressed as the count of acetylated fraction corrected for the activity of the 0-CAT vector.

Nuclear Extraction and Gel Retardation Analyses-- Nuclear extraction and gel retardation analyses were performed as described previously (30). The oligonucleotide probe that was used corresponds to the -240 to -266 fragment, which includes the TRE-2 site (see under "Results and Discussion").

Materials-- Dulbecco's modified Eagle's medium was purchased from Life Technologies, Inc. Penicillin and streptomycin were obtained from M. A. Bioproducts (Walkersville, MD). The pGEM3Zf(+) vector was purchased from Promega (Madison, WI). The [alpha -32P]dCTP and deoxycytidine thiotriphosphate (1000 Ci/ml) were purchased from Amersham Pharmacia Biotech. All other chemicals were obtained from Nakarai Chemicals Ltd. (Kyoto, Japan). Anti-c-Jun, anti-Jun B, anti-Jun D, anti-c-Fos, anti-NF-kappa B, and anti-Fra-1 antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

    RESULTS AND DISCUSSION
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Identification and Structure of the Human Cystatin A Gene-- A human genomic phage library was screened with a 32P-labeled, full-length human cystatin A cDNA (6). Of the 1 × 106 clones screened, one clone (pcHCA) was identified that intensely hybridized with the cystatin A cDNA probe. DNA sequence analysis revealed that pcHCA contained the second and the third exon of the cystatin A gene (Figs. 1 and 2). In order to isolate the first exon and the promoter region, PCR was performed with the AP1/HCA1 primer pair and the AP2/HCA2 primer pair (see "Experimental Procedures"). Two fragments were obtained, one 648 bp and the other 2672 bp. These fragments were subcloned into pCRTM 2.1 vector (pTA648 and pTA2672; see Fig. 1), and DNA sequence analysis was performed. These fragments contained the first exon with the 5'-untranslated region (Figs. 1 and 2). In order to isolate the first exon and the first intron, PCR was performed with the AP3/HCA3 primer pair and the AP4/HCA4 primer pair. A fragment of 4 kb (pTA4k) was amplified, and DNA sequence analysis revealed that the fragment contained the first exon with a portion of the first intron. From these results, cystatin A was shown to contain three exons and two introns. The first, second, and third exons consisted of coding sequences of the cystatin A gene that were 66, 102, and 126 bp in length (Fig. 2). The second intron was approximately 3.6 kb in length, and the first intron was 14 kb in length, as determined by PCR using oligomers coding the first and the second exon (data not shown). We have previously shown that TPA increases the level of mRNA in SVHK cells (6). Therefore, the transcription initiation site of the cystatin A gene was determined by the primer extension method using RNA prepared from TPA-treated SVHK cells. The transcription initiation site was located 55 bp upstream from the first translation site (Fig. 2, A).


View larger version (10K):
[in this window]
[in a new window]
 
Fig. 1.   Structure of the human cystatin A gene. The structure of the gene is schematically represented by the bar at the top of the diagram. Exons are indicated by boxes. pcHCA, pTA648, pTA2672, and pTA4k are the names of clones obtained by the library screening or by the PCR procedure (see "Experimental Procedures").


View larger version (74K):
[in this window]
[in a new window]
 
Fig. 2.   Nucleotide sequence of the human cystatin A gene. The deduced amino acid sequence is shown below the nucleotide sequence. The transcription start site is shown as boldface letter A. The putative polyadenylation site, TRE-1, TRE-2, TRE-3, and the AP2 site are underlined. The star indicates the stop codon. The numbers on the left and right indicate the nucleotide and amino acid numbers, respectively. The nucleotides corresponding to the reported cDNA sequences are underlined.

Cysteine proteinase inhibitors have been subdivided into three families based on primary structure, molecular weight, number of disulfide bonds, and subcellular localization (5). Family 1 cystatins (cystatins A and B) consist of approximately 100 amino acid residues (11-12 kDa) and lack disulfide bonds. Family 2 cystatins (cystatins C, S, and D) are approximately 120 amino acids in length (13-14 kDa) and contain two disulfide bonds. Family 3 cystatins, also known as the kininogen family, contain nine disulfide bonds. The human cystatin A gene consists of three exons and two introns similar to cystatin B (family 1), cystatin C (family 2), cystatin S (family 2), and cystatin D (family 2) (31-34). DNA sequence analyses showed that the 5'-flanking region of the human cystatin A gene did not contain a CAAT box or a TATA box. The other cystatin genes, except for cystatin C, also do not contain these sites.

Identification of the Basal Promoter Region of the Human Cystatin A Gene-- In order to determine the basal promoter region of the human cystatin A gene, six deletion fragments spanning from +77 to -2595 in the 5'-flanking region were fused with the CAT gene and transfected into SVHK cells (Fig. 3). The construct containing the +77 to -2595 fragment (p2672CAT) expressed a CAT activity level 13 times as high as the reverse-oriented construct (Fig. 3) or the constructs with vector but with no flanking region (data not shown). These data indicate that the 5'-flanking region of the human cystatin A gene contains a sequence that confers promoter activity. Deletion of the p2672CAT fragment up to -238 demonstrated minimal loss in basal activity. When the 5'-flanking region was deleted to the -68 position, the CAT activity was markedly depressed, suggesting that the most proximal -238 bp of the 5'-flanking region is essential for the basal transcription.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 3.   Transcriptional activity of the cystatin A promoter. CAT expression vectors with various lengths of the promoter region of the cystatin A gene (5 µg each) were co-transfected into 1 × 105 SVHK cells with an internal control vector, pSV-beta -galactosidase (2 µg). Forty-eight hours after the transfection, the cells were harvested, and extracts were assayed for CAT and beta -galactosidase activity. T1, T2, and T3 indicate the position of the TRE sites. The average CAT activities relative to the promoterless vector 0-CAT vector were obtained from at least three independent experiments 48 h posttransfection.

Within -68 to -238, the cystatin A promoter contains an AP-2-like sequence (TCCCCATGCC; -75 to -84). AP-2 is an enhancer-binding protein that has been purified and cloned from HeLa cells, and this protein specifically interacts with the consensus sequence (T/C)C(C/G)CC(A/C)N(GCG/CGC) (35). Preliminary analysis showed that deletion of the AP-2 region decreased the basal promoter activity by one-third. The AP-2-like site might contribute to the basal transcription of human cystatin A gene.

The TRE-2 Site (-272 to -278) Is Critical for the Up-regulation of the Cystatin A Gene by TPA-- Cystatin S, which is highly expressed in the salivary gland, is induced by the beta -adrenergic agonist isoprotererol (36). Previously, we have reported that cAMP and TPA increases the mRNA level of cystatin A in SVHK cells (6). So far, there is no evidence for the TPA-dependent induction of other cystatins. To determine whether transcription of the human cystatin A gene is stimulated by TPA, five deletion constructs were transfected into SVHK cells in the presence or absence of TPA. The results showed that the construct containing the fragment +77 to -478 responded to TPA stimulation. The CAT activity level increased 3-fold following a 24-h exposure to TPA (Fig. 4). Consistent with the fact that the effect of TPA is mediated by PKC, the TPA-dependent cystatin A promoter activity was mimicked by other PKC activators, 1-oleoyl-2-acetylglycerol and mezerein (Fig. 5A). 4-O-methyl-phorbol 12-myristate 13-acetate, a very weak PKC activator, produced much less effect on the promoter activity. Furthermore, the effect of TPA was inhibited by the PKC inhibitor 1-(5-isoquinoline-sulfonyl)-2-methyl piperazine dihydrochloride (Fig. 5B).


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of TPA on cystatin A promoter activity. Various CAT expression vectors were co-transfected into SVHK cells and incubated for 24 h. The transfected cells were then cultured in the presence () or absence (square ) of TPA (10 ng/ml) for 24 h, and the level of CAT activity was measured. The average CAT activities relative to the promoterless vector 0-CAT vector were obtained from at least three independent experiments.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of PKC activators and inhibitor on cystatin A promoter activity. p648CAT vector was transfected into SVHK cells, and the cells were treated with 1-oleoyl-2-acetylglycerol (100 µg/ml), mezerein (1 µM), or 4-O-methyl-phorbol 12-myristate 13-acetate (200 ng/ml) (A) or with TPA (10 ng/ml) or 1-(5-isoquinoline-sulfonyl)-2-methyl piperazine dihydrochloride (100 µM) for 24 h (B). The average CAT activities relative to the promoterless vector 0-CAT vector were obtained from at least three independent experiments.

There are two putative TPA responsive elements (TRE-1, -189 to -195; TRE-2, -272 to -278) and one AP-2 responsive site (-74 to -83) within the +77 to -478 region of the cystatin A gene (Fig. 2). In order to determine the critical region of the TPA regulatory site, three TRE-deleted constructs were transfected into SVHK cells. Deletion of the T-2 region (-272 to -278) or the T-2 plus T-1 region (-189 to -195) completely abolished the TPA responsiveness (Fig. 6). Conversely, deletion of T-1 showed no significant loss in TPA responsiveness. These results indicate that the sequence -272 to -278 (TRE-2) is responsible for the TPA stimulation.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 6.   Effects of TPA on various TRE-deleted p648CAT vectors. Various TRE-deleted p648CAT vectors were transfected into SVHK cells, and the cells were treated with TPA (10 ng/ml) for 24 h. p648CATDelta T1CAT, TRE-1 site (-189 to -198)-deleted p648CAT vector; p648CATDelta T2CAT, TRE-2 site (-272 to - 278)-deleted p648CAT vector; p648CATDelta T12CAT, TRE-1, TRE-2-deleted p648CAT vector. The average CAT activities relative to the promoterless vector 0-CAT vector were obtained from at least three independent experiments. square , medium alone; , TPA (10 ng/ml).

In keratinocytes, TPA is a potent inducer of differentiation and increases the expression of CE precursor protein(s), as well as transglutaminase. TRE sites have been identified in a number of differentiation-related genes, such as loricrin, involucrin, small proline-rich protein(s), and transglutaminase 1 (19-23). Our study revealed that the TRE-2 region (-272 to -278) of the cystatin A gene was critical for the TPA-induced promoter activity. This is consistent with a common controlling mechanism for the expression of CE precursor proteins, as well as their cross-linking enzyme, transglutaminase 1.

c-Jun, JunD, and c-Fos Bind to the TRE-2 Region and Increase the Cystatin A Promoter Activity-- The AP-1 protein, which is a complex consisting of Jun and Fos family proteins, binds to TREs and regulates the TPA-inducible genes. In order to determine the binding protein(s) in the TRE-2 region of the human cystatin A gene, a 38-bp synthetic oligonucleotide representing the TRE-2 region (-272 to -278 bp) was evaluated using a DNA gel shift assay. Incubation of the oligonucleotide with the nuclear extract from TPA-treated SVHK cells yielded three DNA-protein binding complexes (Fig. 7, lane 2). The specificity of the binding was verified by a competition assay using the same (Fig. 7, lane 4) or unrelated (Fig. 7, lane 5) unlabeled oligonucleotides in excess of 100 moles. Furthermore, anti-c-Jun, anti-JunD, and anti-c-Fos antibodies decreased the specific bands, whereas supershifted bands appeared near the top of the lane (Fig. 7, lanes 6, 8, and 9). A supershifted band was not detected by the addition of anti-JunB, anti-Fra-1, or anti-NF-kB antibodies (Fig. 7, lanes 7, 10, and 11).


View larger version (131K):
[in this window]
[in a new window]
 
Fig. 7.   Gel shift analysis of nuclear extracts from TPA-treated SVHK cells. The nuclear extracts from TPA-treated SVHK cells were reacted with the synthesized oligomer that contained the TRE-2 region. Lane 1, probe without nuclear extract; lane 2, nuclear extract from TPA-treated SVHK cells reacted with the synthesized oligomer containing the TRE-2 region; lane 3, nuclear extract from TPA-treated SVHK cells plus the oligomer containing the TRE consensus sequence; lane 4, nuclear extract from TPA-treated SVHK cells with an excess of 100 moles of unlabeled probe; lane 5, nuclear extract from TPA-treated SVHK cells with the oligomer containing the NF-kappa B binding consensus sequence; lane 6, nuclear extract from TPA-treated SVHK cells with the anti-c-Jun antibody; lane 7, nuclear extract from TPA-treated SVHK cells with the anti-c-JunB antibody; lane 8, nuclear extract from TPA-treated SVHK cells with the anti-JunD antibody; lane 9, nuclear extract from TPA-treated SVHK cells with the anti-c-Fos antibody; lane 10, nuclear extract from TPA-treated SVHK cells with the anti-Fra-1 antibody; lane 11, nuclear extract from TPA-treated SVHK cells with the anti-NF-kappa B antibody. The arrows indicates the supershifted bands.

In order to determine the effects of these AP-1 related proteins on the transcription of cystatin A, various expression vectors of the Jun and Fos family proteins were transfected into SVHK cells. Co-transfection of the p648CAT vector with the c-Jun and c-Fos expression vectors or the JunD and c-Fos expression vectors resulted in an increase in the CAT activity level (Fig. 8). This finding suggests that the nuclear proteins that bind to the TRE-2 region are most likely composed of c-Jun and c-Fos or of JunD and c-Fos.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 8.   Effects of AP-1 family proteins on cystatin A promoter activity. Various AP-1 family expression vectors (3 µg) were transfected into SVHK cells with the p648CAT vector and incubated for 48 h. The concentration of TPA was 10 ng/ml. The average CAT activities relative to the promoterless vector 0-CAT vector were obtained from at least three independent experiments.

It has been reported that cystatin A is expressed in the upper spinous layer to the granular layer of the normal epidermis (37). Immunohistochemistry of the normal epidermis revealed that the c-Fos protein is localized in the upper spinous and granular cell layers, whereas the c-Jun protein is localized in the granular cell layer. Fra-1 is expressed in all of the epidermal cell layers except for the basal cell layer. Conversely, JunB and JunD are present in all of the epidermal cell layers (38). Our finding that the cystatin A gene is regulated by c-Jun and c-Fos, or by c-Jun and JunD, is compatible with the expression pattern of the AP-1 protein family in the epidermis.

Transcription of the Cystatin A Gene Is Increased by Transfection of the PKC-alpha Expression Vector-- PKC is a large family of proteins consisting of at least 11 isozymes (39). PKC-alpha , -beta I, -beta II, and -gamma are the classical PKC proteins that are calcium- and diacylglycerol-dependent. PKC-delta , -epsilon , -eta , -theta , and -µ are the novel PKCs, which do not require calcium for activation. PKC-zeta and -tau are the atypical PKCs, which require neither calcium nor diacylglycerol for activation. TPA activates classical and novel PKCs but not atypical PKCs. The epidermal keratinocytes contain PKC-alpha , -delta , -epsilon , -eta , and -zeta (40).

In order to determine the PKC isozyme(s) responsible for cystatin A gene expression, we co-transfected SVHK cells with the p648CAT vector and various PKC isozyme expression vectors. Consistent with TPA-induced activation of endogenous PKC(s), cystatin A promoter activity was increased by TPA in SVKH cells transfected with the control vector (Fig. 9, C). Transfection of PKC-delta , -epsilon , -eta , or -zeta had no effect on the cystatin A promoter activity as compared with the transfection of the control vector. Although TPA also increased the promoter activity of SVHK cells transfected with PKC-delta , -epsilon , -eta , or -zeta , the increase was not statistically significant as compared with that of the cells transfected with the control vector (Fig. 9, delta , epsilon , eta , and zeta ). Cystatin A promoter activity, however, was significantly stimulated by co-transfection of p648CAT and the PKC-alpha vectors, which was further stimulated by TPA (Fig. 9, alpha ). These results suggest that PKC-alpha is responsible for the stimulation of the human cystatin A promoter activity. There are several reports concerning the localization of PKC isozymes in the epidermis (41-43). In normal skin, PKC-eta is expressed in the uppermost granular layer (43), whereas PKC-alpha mRNA is expressed from the basal to the spinous layers (42). Because cystatin A is expressed in the upper spinous layer and the granular layer, there would be other transcription factors (either stimulatory or inhibitory) that regulate the differentiation-specific expression of cystatin A in the epidermis.


View larger version (56K):
[in this window]
[in a new window]
 
Fig. 9.   Effects of PKC isozyme expression vectors on cystatin A promoter activity. Various PKC isozyme expression vectors (3 µg) were transfected into SVHK cells with the p648CAT vector and incubated for 24 h. The transfected cells were then cultured in the presence or absence of TPA (10 ng/ml) for 24 h. C, control vector; alpha , PKC-alpha ; delta , PKC-delta ; epsilon , PKC-epsilon ; zeta , PKC-zeta ; eta , PKC-eta . The average CAT activities relative to the promoterless vector 0-CAT vector were obtained from at least three independent experiments. square , medium; , TPA (10 ng/ml).

In this study, we characterized the structure of the human cystatin A gene, including the 5'-upstream region. The cystatin A gene was shown to be regulated by PKC pathway, similar to other CE precursor proteins (6, 44). The characterization of the AP1-dependent signaling pathway via specific PKC isozymes will clarify the nature of the regulation and will elucidate the molecular mechanisms of keratinocyte differentiation.

    ACKNOWLEDGEMENTS

The technical assistance of Y. Kotani and K. Takahashi and the secretarial assistance of Y. Maekawa are greatly appreciated.

    FOOTNOTES

* This study was supported in part by Grants 08457233 (to H. I.) and 09770598 (to H. T.) from Ministry of Education, Science, Sports and Culture of Japan and by grants from the Ministry of Health and Welfare, Japan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AB007773 and AB007774.

Dagger To whom correspondence should be addressed. Tel.: 81-166-65-2111; Fax: 81-166-65-7751; E-mail: ht{at}asahikawa-med.ac.jp.

dagger Deceased on December 1, 1994.

1 The abbreviations used are: CE, cornified cell envelope; CAT, chloramphenicol acetyltransferase; PCR, polymerase chain reaction; PKC, protein kinase C; SVHK, SV40-transformed human keratinocyte; TPA, 12-O-tetradecanoylphorbol-13-acetate; TRE, TPA responsive element; bp, base pair(s).

    REFERENCES
Top
Abstract
Introduction
Procedures
Results & Discussion
References

  1. Brzin, J., Kopitar, M., Turk, V., and Machleidt, W. (1983) Hoppe-Seyler's Physiol. Chem. 364, 1475-1480[Medline] [Order article via Infotrieve]
  2. Brzin, J., Kopitar, M., and Turk, V. (1982) FEBS Lett. 138, 193-197[CrossRef][Medline] [Order article via Infotrieve]
  3. Green, G. D. J., Kembhavi, A. A., and Davies, M. E. (1984) Biochem. J. 218, 939-946[Medline] [Order article via Infotrieve]
  4. Jarvinen, M. (1978) J. Invest. Dermatol. 71, 114-118[Abstract]
  5. Barrett, A. J. (1987) Trends Biochem. Sci. 12, 193-196[CrossRef]
  6. Takahashi, H., Kinouchi, M., Wuepper, K. D., and Iizuka, H. (1997) J. Invest. Dermatol. 108, 843-847[Abstract]
  7. Simon, M. (1994) The Keratinocyte Handbook, pp. 275-292, Cambridge University Press, Cambridge
  8. Hohl, D. (1990) Dermatologica 180, 201-211[Medline] [Order article via Infotrieve]
  9. Eckert, R. L., Yaffe, M. B., Crish, J. F., Murthy, S., Rorke, E. A., and Welter, J. F. (1993) J. Invest. Dermatol. 100, 613-617[Abstract]
  10. Yamada, K., Takamori, K., and Ogawa, H. (1987) Arch. Dermatol. Res. 279, 194-197[Medline] [Order article via Infotrieve]
  11. Eckert, R. L., and Green, H. (1986) Cell 46, 583-589[Medline] [Order article via Infotrieve]
  12. Hohl, D., Mehrel, T., Lichti, U., Turner, M. L., Roop, D. R., and Steinert, P. M. (1991) J. Biol. Chem. 266, 6626-6636[Abstract/Free Full Text]
  13. Kartasova, T., and van de Putte, P. (1988) Mol. Cell. Biol. 8, 2195-2203[Medline] [Order article via Infotrieve]
  14. Steinert, P. M., and Marekov, L. N. (1995) J. Biol. Chem. 270, 17702-17711[Abstract/Free Full Text]
  15. Ruhrberg, C., Hajibagheri, M. A., Simon, M., Dooley, T. P., and Watt, F. M. (1996) J. Cell Biol. 134, 715-729[Abstract]
  16. Ishida-Yamamoto, A., Kartasova, T., Matsuo, S., Kuroki, T., and Iizuka, H. (1997) J. Invest. Dermatol. 108, 12-16[Abstract]
  17. Hawley-Nelson, P., Stanley, J. R., Schmidt, J., Gullino, M., and Yuspa, S. (1982) Exp. Cell Res. 137, 155-167[Medline] [Order article via Infotrieve]
  18. Mafson, R. A., Steinberg, M. L., and Defendi, V. (1982) Cancer Res. 42, 4600-4605[Abstract]
  19. Takahashi, H., and Iizuka, H. (1993) J. Invest. Dermatol. 100, 10-15[Abstract]
  20. Welter, J. F., Crish, J. F., Agarwal, C., and Eckert, R. L. (1995) J. Biol. Chem. 270, 12614-12622[Abstract/Free Full Text]
  21. Lopez-Bayghen, E., Vega, A., Cadena, A., Granados, S. E., Jave, L., Gariglio, P., and Alvares-Saras, L. M. (1996) J. Biol. Chem. 271, 512-520[Abstract/Free Full Text]
  22. DiSepio, D., Jones, A., Longley, M. A., Bundman, D., Rothnagel, J. A., and Roop, D. R. (1995) J. Biol. Chem. 270, 10792-10799[Abstract/Free Full Text]
  23. Yamanishi, K., Inazawa, J., Liew, F.-W., Nonomura, K., Ariyama, T., Yasuno, H., Abe, T., Doi, H., Hirano, J., and Fukushima, S. (1992) J. Biol. Chem. 267, 17858-17863[Abstract/Free Full Text]
  24. Steinberg, M. L., and Defendi, V. (1983) J. Invest. Dermatol. 81, 131S-136S[Medline] [Order article via Infotrieve]
  25. Takahashi, H., Tamura, T., Tsutsui, M., and Iizuka, H. (1990) J. Dermatol. 17, 457-464[Medline] [Order article via Infotrieve]
  26. Maniatis, T., Fritsch, E. H., and Sambrook, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., Chapter 13, Cold Spring Harbor Laboratory, Cold Spring Habor, NY
  27. Ohno, S., Akita, Y., Konno, Y., Imajoh, S., and Suzuki, K. (1988) Cell 53, 731-741[Medline] [Order article via Infotrieve]
  28. Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M., and Danielsen, M. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 7413-7417[Abstract]
  29. Neuman, J. R., Morency, C. A., and Russian, K. D. (1987) Biotechniques 5, 441
  30. Takahashi, H., Kobayashi, H., and Iizuka, H. (1995) Arch. Dermatol. Res. 287, 740-746[Medline] [Order article via Infotrieve]
  31. Pennacchio, L. A., Lehesjoki, A.-E., Stone, N. E., Willour, V. L., Virtaneva, K., Miao, J., D'Amato, E., Ramirez, L., Faham, M., Koskiniemi, M., Warrington, J. A., Norio, R., Chapelle, A., Cox, D. R., and Myers, R. M. (1996) Science 271, 1731-1734[Abstract]
  32. Abrahamson, M., Olafsson, I., Palsdottir, A., Ulvback, M., Lundwall, A., and Grubb, J. A. (1990) Biochem. J. 268, 287-294[Medline] [Order article via Infotrieve]
  33. Saitoh, E., Kim, H.-S., Smithies, O., and Maeda, N. (1987) Gene 61, 329-338[Medline] [Order article via Infotrieve]
  34. Freije, J. P., Abrahamson, M., Olafsson, I., Velasco, I., Grubb, A., and Lopez-Otin, C. (1991) J. Biol. Chem. 266, 20538-20543[Abstract/Free Full Text]
  35. Imagawa, M., Chiu, R., and Karin, M. (1987) Cell 51, 251-260[Medline] [Order article via Infotrieve]
  36. Shaw, P. A., Cox, J. L., Barka, T., and Naito, Y. (1988) J. Biol. Chem. 263, 18133-18137[Abstract/Free Full Text]
  37. Tezuka, T., Qing, J., Saheki, M., Kushida, S., and Takahashi, M. (1994) Dermatology 188, 21-24[Medline] [Order article via Infotrieve]
  38. Welter, J. F., and Eckert, R. L. (1995) Oncogene 11, 2681-2687[Medline] [Order article via Infotrieve]
  39. Nishizuka, Y. (1992) Science 258, 607-614[Medline] [Order article via Infotrieve]
  40. Dlugosz, A. A., Mischak, H., Muchinski, J. F., and Yuspa, H. S. (1992) Mol. Cell. Biol. 12, 286-292
  41. Leibersperger, H., Gschwendt, M., Gernold, M., and Marks, F. (1991) J. Biol. Chem. 266, 14778-14787[Abstract/Free Full Text]
  42. Wevers, A., Wirnitzer, U., Schaarschmidt, H., Hagemann, L., and Mahrle, G. (1992) Arch. Dermatol. Res. 284, 5-7[Medline] [Order article via Infotrieve]
  43. Koizumi, H., Kohno, Y., Osada, S., Ohno, S., Ohkawara, A., and Kuroki, T. (1993) J. Invest. Dermatol. 101, 858-863[Abstract]
  44. Stanwell, C., Denning, M. F., Rutberg, S. E., Cheng, C., Yuspa, S. H., and Dlugosz, A. A. (1996) J. Invest. Dermatol. 106, 482-489[Abstract]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.